A study of evaluating the phenotypic presentation trends based on initial clinical, biomarkers and transthoracic echocardiographic (TTE) data of tafamidis in patients with Transthyretin amyloid cardiomyopathy (ATTR-CM)
Latest Information Update: 08 Dec 2021
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloid light-chain amyloidosis; Cardiomyopathies; Transthyretin-related hereditary amyloidosis
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 08 Dec 2021 New trial record